We have investigated the activity of ITF2357, a novel hydroxamate histone deacetylase inhibitor, on multiple myeloma (MM) and acute myelogenous leukemia (AML) cells in vitro and in vivo. ITF2357 induced apoptosis in 8/9 MM and 6/7 AML cell lines, as well as 4/4 MM and 18/20 AML freshly isolated cases, with a mean IC 50 of 0.2 lM. ITF2357 activated the intrinsic apoptotic pathway, upregulated p21 and downmodulated Bcl-2 and Mcl-1. The drug induced hyperacetylation of histone H3, H4 and tubulin. When studied in more physiological conditions, ITF2357 was still strongly cytotoxic for the interleukin-6 (IL-6)-dependent MM cell line CMA-03, or for AML samples maximally stimulated by co-culture on mesenchymal stromal cells (MSCs), but not for the MSCs themselves. Interestingly, ITF2357 inhibited the production of IL-6, vascular endothelial growth factor (VEGF) and interferon-c by MSCs by 80-95%. Finally, the drug significantly prolonged survival of severe combined immunodeficient mice inoculated with the AML-PS in vivo passaged cell line already at the 10 mg/kg oral dose. These data demonstrate that ITF2357 has potent anti-neoplastic activity in vitro and in vivo through direct induction of leukemic cell apoptosis. Furthermore, the drug inhibits production of growth and angiogenic factors by bone marrow stromal cells, in particular IL-6 and VEGF.
Introduction
Cell cycle progression and cell death are regulated by many proteins including histones, transcription factors and regulatory proteins, which are in turn controlled in part by acetylation of specific residues. Histone deacetylases (HDAC) are a family of at least 18 different nuclear and cytoplasmic molecules grouped into four classes (reviewed in de Ruijter et al., 1 Arney and Fisher, 2 Bolden et al., 3 and Dokmanovic and Marks 4 ). Several histone deacetylase inhibitor (HDACi) have been synthesized and shown to affect the growth, differentiation and survival of tumor cells of different origin (reviewed in Kelly and Marks 5 ). One class of HDACi is the hydroxamate family of compounds whose prototype is suberoyl anilide hydroxamic acid (SAHA, Vorinostat). 1, 6 SAHA inhibits class I and class II HDACs, is being tested in phase I and phase II trials for solid and hematological cancers and has recently been approved by the Food and Drug Administration for the treatment of cutaneous T-cell lymphoma. [5] [6] [7] Deregulation of transcription factors and HDACs is a hallmark of many leukemias and lymphomas. 8, 9 Indeed several HDACi have shown promising anti-tumoral activity in multiple myeloma (MM), acute myelogenous leukemia (AML) and other hematological neoplasias in vitro and in vivo. 7, [10] [11] [12] [13] [14] Acute leukemias localize mostly in the bone marrow with marrow stroma providing positive signals, growth and angiogenic factors that support leukemia proliferation and progression. In particular in MM, the bone marrow microenvironment induces growth, survival and drug resistance through cell-cell adhesion and release of cytokines such as interleukin-6 (IL-6) (reviewed in Sirohi et al. 15 ). Stromal cells also secrete angiogenic factors such as vascular endothelial growth factor (VEGF), which promote tumor vascularization and neoplastic growth. 16 Thus, the investigation of the effects of new antineoplastic drugs in leukemia and myeloma is best performed in systems reconstituting the bone marrow microenvironment. [17] [18] [19] ITF2357 is a new hydroxamate HDACi that inhibits class I and class II enzymes in different cell types. 20 It selectively induces apoptosis of hepatoma cells but not primary hepatocytes. 21, 22 ITF2357 also has anti-inflammatory activity and inhibits the secretion of the tumor necrosis factor-a (TNF-a), IL-1, IL-6 and interferon-g (IFN-g) cytokines induced by lipopolysaccharide (LPS) in peripheral blood mononuclear cells. 23, 24 We have investigated the activity of ITF2357 against MM and AML cells, in vitro and in vivo using both cell lines and freshly isolated samples cultured on a feeder layer of bone marrow-derived multipotent mesenchymal stromal cells (MSCs).
Materials and methods

Reagent and cells
ITF2357 (Italfarmaco, Milano, Italy; patent WO 97/43251, US 6034096) and SAHA were synthesized by Italfarmaco, and their purity was confirmed by HPLC. 20 The chemical structure of ITF2357 is shown in the Supplementary Figure 1 (Chemical Abstract Number 732302-99-7).
All MM cell lines were grown in Iscove's modified Dulbecco's medium (Cambrex Bio Science, Verviers, Belgium) with 10% fetal calf serum (FCS) (Euroclone, Wetherby, West Yorkshire, UK), 2 mM glutamine (Euroclone) and 110 mM gentamycin (PHT Pharma, Milano, Italy). In the case of the IL-6-dependent line CMA-03, 10 ng/ml rhIL-6 (Biosource International, Camarillo, CA, USA) was added. 25 The AML cell lines HL-60 (M2), THP-1 (M5), U937 (M5), Kasumi (M2), KG1 (M1), TF-1 (M6) and GFD8 (M1) were grown in RPMI1640 supplemented as above. Bone marrow mononuclear cells were isolated from MM patients and plasma cells purified (X90% purity) by positive selection with anti-CD138 magnetic-activated cell separation microbeads (Miltenyi Biotec, San Diego, CA, USA). Mononuclear cells from bone marrow or peripheral blood of AML patients with at least 80% blasts were cultured in StemSpanSFEM medium (Stem Cell Technologies, Vancouver, Canada).
To generate MSCs, bone marrow mononuclear cell were adhered to plastic in DMEM low glucose medium (Gibco Invitrogen, Carlbad, CA, USA) and 10% FCS (Euroclone). Once adherent cells reached confluence, cells were detached with trypsin/ethylenediaminetetraacetic acid, plated at 0.5 Â 10 6 / 175 cm 2 flask and fed weekly. MSCs had adipogenic and osteogenic potential, as described previously 26 (data not shown). Only one-third or one-fourth passage cells were used.
Cytotoxicity assays
Cytotoxicity assays were performed using the alamar blue vital dye essentially as described. 27 Briefly, cell lines or MSCs were plated in the presence or absence of 0.1-1 mM ITF2357 or SAHA. After 2 days of culture, alamar blue solution (Biosource International) was added. After overnight incubation, the plates were read in a fluorimeter (Tecan Austria GmbH, Salzburg, Austria) with excitation at 535 nm and emission at 590 nm.
FACS analyses
Apoptosis was measured by Annexin V-PE/ 7AAD double staining using the kit from BD Biosciences (San José, CA, USA) and fluorescence-activated cell sorter (FACS) analysis (FacsScan, BD Biosciences). Caspase 3 activation was measured using AlexaFluor488-labeled anti-cleaved caspase 3 antibody (Cell Signalling Technology, Beverly, MA, USA), according to the manufacturer's instructions and FACS analysis. For measurement of a-tubulin acetylation, cells were treated for 1 h with ITF2357 or medium, permeabilized and stained with antitubulin or acetyl-tubulin antibodies (Sigma-Aldrich, St Louis, MO, USA) followed by FITC-labeled rabbit anti-mouse polyclonal antibody (Sigma).
Colony assays
Three thousand MM or AML cells were added to 3 ml methylcellulose (MethoCult SF BIT StemCell Technologies Inc., Vancouver, BC, Canada) and plated in duplicate in 55 mm dishes (Nalge Nunc International, Rochester, NY, USA). Plates were incubated at 371C for 15-21 days and colonies counted under an inverted microscope.
Co-culture of leukemic cells with MSCs
For all co-cultures, MSCs were plated at 5000/well in 96-well plates and incubation was carried on for 48-72 h at 371C in order to reach confluence. CMA-03 cells were then added at 5000/well and AML cells at 1 Â 10 5 cells/well in medium in the presence or absence of MSCs or 10 ng/ml rhIL-6 and with different concentrations of ITF2357. Medium was replaced twice weekly. After different time intervals, non-adherent cells were collected and stained with propidium iodide (5 mg/ml, Sigma) and FITC-conjugated anti-CD138 (for CMA-03) or anti-CD33 MAb (for AML). Stained cells were analyzed on the FACS to determine cell viability and identity. Total number of live cells was also counted by Trypan blue exclusion.
Western blotting
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting were performed according to standard procedures using total cellular extracts or nuclear extracts in the case of histone analysis. 20 The following antibodies were used: p21, Bcl2, Bax, Mcl-1, caspases 8 and actin (Santa Cruz, Heidelberg, Germany), caspase 9 (Cell Signalling), a-tubulin and acetyltubulin (Sigma), acetyl-histone H3 and acetyl-histone H4 (Upstate Biotechnology, Lake Placid, NY, USA), and detected by ECL (Amersham-Pharmacia Biotech, Cologno Monzese, Italy). Detection was performed using horseradish peroxidase labeled secondary antibodies (Santa Cruz) and chemiluminescence.
Quantitative PCR analysis
Purified RNA was treated with DNase (Qiagen, Sp.A, Milan, Italy) and purified by the RNeasy MiniElute cleanup kit (Qiagen). cDNA synthesis was performed with 500 ng of RNA using oligo (dT) 12-18 and the Superscript Reverse Transcriptase II (Invitrogen) followed by RNase H treatment. Real-time PCR analysis was performed using the following primer sets: P21 forward: 5 0 -ATGAAATTCACCCCCTTTCC; P21 reverse: 5 0 -AGGTGAGGGGACTCCAAAGT; Bcl-2 forward: 5 0 -GCCCTGT GGATGACTGAGTA; Bcl-2 reverse: 5 0 -GAGACAGCCAGGAG AAATCAA; 18S rRNA forward: 5 0 GCTGCTGGCACCAGACTT; 18S rRNA reverse: 5 0 -CGGCTACCACATCCAAGG. Amplification was performed on iCycler iQ system using the iQ SYBR Green PCR Supermix (Bio-Rad, Laboratories, Segrate, Italy) according to the manufacturer's instructions. Relative gene expression was calculated using 18S rRNA as normalization gene.
Cytokine production by MSCs
MSCs were plated with increasing concentrations of ITF2357 and supernatants collected at 24 h. Cytokines were measured by multiplex technology, using a Bio-Plex cytokine assay kit (BioRad) detecting granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-g, IL-1b, IL-6, IL-8, IL-10, IL-12(p70), macrophage inflammatory protein (MIP)-1a, MIP-1b, TNF-a and VEGF. The assay was carried out according to the manufacturer's instructions. The quantification of the analytes in each sample was determined using high sensitivity standard curves and a fiveparameters logistic regression analysis, using the Bio-Plex Manager 3.0 software (Bio-Rad).
In vivo model
In vivo passaged AML-PS cells (5 Â 10 6 ) were inoculated in the tail vein of 5-week-old severe combined immunodeficient (SCID) mice (CB17/IcrHanHsd-scid, Harlan, Italy). Mice were randomized and divided into four groups: Vehicle (ten mice), ITF2357 1 mg/kg (nine mice), ITF2357 10 mg/kg (ten mice) and ITF2357 100 mg/kg (seven mice). On the 4th day after tumor cells injection, the drug treatment was started and maintained until day 55. ITF 2357 was suspended in 5% methylcellulose and administered daily by gavage in a volume of 0.2 ml/mouse. Survival of the animals was recorded daily and necropsy was performed on all animals. The presence of CD33 þ tumor cells was confirmed in several animals by immunophenotypic analysis of spleen cells.
Statistical analyses
The significance of ITF2357 effect in vitro assays was analyzed by one-way analysis of variance. Statistical analysis of survival was carried out by Log Rank test using GraphPad Prism 3.0 software.
Results
ITF2357 is cytotoxic for MM and AML lines and freshly isolated samples
We first investigated the effect of ITF2357 on nine MM and seven AML cell lines in vitro. ITF2357 was strongly cytotoxic in 8 out of 9 MM and 6 out of 7 AML cell lines with an IC 50 ranging from 0.07 to 0.40 mM (mean 0.17 and 0.23 mM for ITF2357 in MM and AML responsive lines, respectively) ( Table 1 ). Only two cell lines, the U266 MM and the GFD8 AML lines, were relatively resistant to ITF2357 under the conditions tested, with IC 50 X1 mM (Table 1, italic). As expected, the prototypic HDACi SAHA tested as control was also cytotoxic, although at 3-4 times higher concentrations (Table 1 ). In order to determine whether ITF2357 also targeted clonogenic cells, we tested its activity in colony assays. ITF2357 completely abolished colony growth of the RPMI8226 and KG1 cell lines with an IC 50 equivalent to that measured in the cytotoxicity assays (0.16 and 0.07 mM, respectively; Figure 1a ). Also SAHA was inhibitory for clonogenic cells with IC 50 from 0.25 to 0.75 mM. These data demonstrate that ITF2357 is cytotoxic for the clonogenic MM and AML cells.
We next determined the cytotoxic activity of ITF2357 and SAHA on leukemic cells freshly isolated from patients. MM cells were purified from four patients by CD138 immunoaffinity columns. Three out of four patients carried a del13q14 deletion and t(4;14) translocation, and one showed a t(11;14) translocation only. The results demonstrate that primary MM cells show a similar sensitivity to ITF2357 as cell lines, with IC 50 ranging from 0.12 to 0.4 mM for the four patients (mean IC 50 ¼ 0.23 mM; Figure 1b and Supplementary Table 1 ). SAHA was also cytotoxic for both MM and AML cells with a mean IC 50 of about 0.6 mM. Samples from 20 AML patients containing at least 80% blasts were similarly analyzed. These samples belonged to M1, M2, M4 and M5 French-American-British (FAB) subtypes, and carried the most common cytogenetic abnormalities including inv (16) Table 2 ). The mean response of all patients' samples is shown in Figure 1b .
ITF2357 induces apoptosis through the intrinsic pathway
ITF2357 was shown to be cytotoxic for MM and AML cells through induction of apoptosis by annexin V/7-AAD staining (data not shown). Activation of procaspase 3 was also analyzed by flow cytometry. The CMA-03 and KG-1 cell lines treated with 0.5 mM ITF2357 expressed cleaved caspase 3 in 57 and 72% of cells, respectively (Figure 1c) . The apoptotic pathway involved was then investigated in more detail by western blotting. Analysis of different caspases revealed that ITF2357 activated the intrinsic pathway dependent upon caspase 9, with appearance of the 37 kDa-cleaved fragment. In contrast, no evidence of triggering of the extrinsic pathway could be obtained, as no procaspase 8 cleavage could be detected in MM or AML cell lines (data not shown; Figure 2a ). Further study of several proteins involved in cell cycle and apoptosis showed that ITF2357 induces strong p21 protein expression at 6 and 24 h and downmodulates Bcl2 and Mcl-1 3-to 4-fold, with maximal effect at 24-48 h (Figures 2a and b) . A transient increase in p21 and decrease in bcl2 gene expression was also observed at the RNA level by quantitative PCR (Figure 2b ). Other proteins involved in apoptosis regulation, in particular Bax and DR4, were not significantly modulated by the drug in the same cell lines (data not shown; Figure 2a ). We conclude that ITF2357 is a strong inducer of apoptosis through the intrinsic pathway in MM and AML cells. Furthermore, ITF2357 rapidly induces p21 and downmodulates the anti-apoptotic proteins Bcl2 and Mcl-1.
ITF2357 hyperacetylates histone H3, H4 and tubulin
We have investigated the effect of ITF2357 on protein acetylation in leukemic cell lines. Western blot analysis showed that the drug induced strong hyperacetylation of histones H3 and H4 (Figure 3a) . The hyperacetylation of histones started to be detectable at 0.12 mM and was very marked at doses of 0.5 mM at 24 h. It was already detectable at 4 h (data not shown). ITF2357 also hyperacetylated tubulin 4-to 6-fold over background with a similar dose-response curve (Figure 3a) . Hyperacetylation of tubulin was confirmed by FACS analysis of acetylated and total tubulin and could be detected already at 1 h (Figure 3b ).
ITF2357 is cytotoxic for MM and AML cells cultured on MSCs
In order to study the anti-tumor activity of ITF2357, a culture system mimicking the bone marrow microenvironment, multipotent MSCs were expanded in culture from normal bone marrows. The cultured MSCs were tested as feeder layer for the IL-6-dependent cell line CMA-03. CMA-03 cells were plated in the presence or absence of MSCs or rhIL-6. Cell growth was measured at different time intervals by total cell count of nonadherent cells, as well as CD138-FITC/propidium iodide /ml with MSCs compared to 0.9 Â 10 6 /ml in the presence of IL-6 alone. Thus MSCs allows CMA-03 cells to grow in vitro at least as efficiently as in the presence of rhIL-6. AML cells isolated from two patients were also cultured in the presence or absence of MSCs for 4 or 16 days, respectively. Cell viability was measured by FACS analysis. As shown in Figure 4b , AML cells maintained in culture with MSCs for up to 16 days retained a high viability (90 and 73% at 4 and 16 days, respectively), compared to cells cultured in medium alone (75 and 32%, respectively). Cell counts revealed that little expansion of the AML cells could be observed in the presence of MSCs at either 4 or 16 days (data not shown), but only a striking maintenance of their viability (Figure 4b ).
We next investigated whether ITF2357 was still cytotoxic for MM and AML cells even when stimulated by MSCs in the coculture system. CMA-03 cells were plated on an MSC feeder layer in the presence of increasing concentrations of ITF2357. The drug was still strongly cytotoxic for CMA-03 cells in these conditions (IC 50 0.37 mM; Figure 5a ). Since the cytotoxic activity of ITF2357 may also have been due to killing of the mesenchymal feeder cells, we verified whether the drug was pro-apoptotic for the MSCs themselves. MSCs were treated with increasing doses of ITF2357 and cell viability measured after 72 h. ITF2357 was not cytotoxic for MSCs up to 1 mM (Figure 5b ). The drug was tested up to 10 mM, at which concentration cell viability was still 71% (data not shown).
Similarly, the response of one AML sample to a fixed dose of ITF2357 (0.1 mM) was analyzed after different times of culture in the presence or absence of MSCs. As shown in Figure 5c respect to untreated controls at day 11 with and without MSCs, respectively. The marginally higher cytotoxicity observed in the absence of MSCs at different time points suggests that MSCs provide some protection from the drug (Figure 5c ). We then tested the response at day 5 of AML samples from four different patients, in all cases cultured on MSCs and using increasing doses of ITF2357. All samples responded with a mean IC 50 of 0.3 mM in these conditions (data not shown; Figure 5d ). We conclude that ITF2357 is highly cytotoxic for freshly isolated MM and AML samples in vitro, even when stimulated by coculture on bone marrow-derived MSCs.
ITF2357 inhibits the production of growth and angiogenic factors by MSCs
Since ITF2357 has been shown previously to inhibit production of several cytokines by peripheral blood mononuclear cells, its effect on cytokine production by MSCs was investigated. Culture supernatant from MSCs alone was collected after 24 h and analyzed for the presence of 12 different cytokines (G-and GM-CSF, IL-6, 8 and 10, IL-12(p70), IL-1-b, IFN-g, MIP-1a and b, TNF-a and VEGF). Out of all these cytokines, the MSCs were found to produce significant amounts only of IL-6 (1800 pg/ml), IL-8 (1900 pg/ml), VEGF (700 pg/ml) and to a lesser extent IFN-g (95 pg/ml). Production of the other cytokines tested was negligible (p25 pg/ml) (data not shown). We next investigated whether ITF2357 inhibited cytokine production by MSCs. The supernatants of MSCs treated for 24 h with increasing concentrations of ITF2357 were analyzed. ITF2357 inhibited IL-6, IFN-g and VEGF by 80-95%, with an IC 50 between 0.25 and 0.5 mM (Figures 6a, b and d ) (Po0.001 at 0.5-10 mM ITF2357). In contrast, IL-8 production was unaffected by ITF2357 treatment up to 10 mM (Figure 6c ). The marginal decrease in IL-8 production at the single dose of 1 mM ITF2357 (Po0.05) was not confirmed in an independent experiment (Figure 6c ). We conclude that ITF2357 strongly and specifically inhibits the production by MSCs of several growth and angiogenic factors important for survival of leukemic cells in vivo.
ITF2357 prolongs survival of leukemia bearing SCID mice
In order to demonstrate therapeutic activity of ITF2357, an in vivo model of AML was set up. AML-PS is a cell line derived from an AML patient and established by in vivo passage in SCID mice after intraperitoneal injection. Anti-leukemic activity of the new HDAC inhibitor ITF2357 J Golay et al and daily oral treatment with different doses of ITF2357 was initiated after 4 days. Survival of animals was recorded. The results demonstrate that ITF2357 had no significant effect at 1 mg/kg (P ¼ 0.36), but showed clear therapeutic activity at the intermediate dose of 10 mg/kg, with median survival of 46 compared to 40 days for the control group (P ¼ 0.0057). The therapeutic effect was even greater at 100 mg/kg, with a median survival time of 50 days (Po0.0001 compared to controls; Figure 7 ). All animals died of tumor as shown by necropsy of the animals and by immunophenotypic analysis of randomly selected cases (CD45 and CD33) (data not shown).
Discussion
We report here that the new HDCAi ITF2357 has a dual antileukemic activity, since it induces apoptosis of both MM and AML cells and inhibits the production of IL-6 and VEGF by MSCs, two soluble factors crucial for leukemia growth and drug resistance. Furthermore, therapeutic activity of ITF2357 was demonstrated in vivo in a SCID mouse model of AML. ITF2357 induced apoptosis of most MM or AML cells lines as well as freshly isolated leukemic samples with a mean IC 50 of 0.20 mM. Furthermore, it was cytotoxic for clonogenic leukemic cells in vitro. Indeed most freshly isolated leukemic cases responded well to ITF2357 and no correlation between response and specific disease subtype based on FAB or genetic alterations was observed. Interestingly levels of ITF2357 corresponding to the IC 50 can be reached in vivo without relevant toxicity.
The possible mechanism of apoptosis was investigated. We show here that ITF2357 induces activation of caspases 3 and 9, but not 8. This is in agreement with previous reports on the mechanism of action of other HDACi such as LAQ824 and LBH589.
3,30-32 Furthermore, we observed that ITF2357 induces p21 protein expression and downmodulates Bcl2 and Mcl1 proteins in both MM and AML cells. Modulation of p21 and bcl2 was observed also at the RNA level, suggesting that this effect was the result of drug-induced transcriptional rather than posttranslational modifications. Other apoptosis-related proteins such as Bax were not affected. Induction of p21 is a hallmark of HDAC inhibitors. 10, 30, 31, 33, 34 Downmodulation of Bcl2 and Mcl1 has also been reported for several other HDACi. 3, [30] [31] [32] 35, 36 Interestingly overexpressed Bcl2 has been shown to lead to resistance to SAHA in animal models of lymphoma, 37 leading support to the hypothesis that the downmodulation of Bcl2 observed here may contribute to ITF2357-triggered apoptosis. 3, 32 Altogether, our data suggest that ITF2357 induces apoptosis through the intrinsic pathway and deregulation of apoptotic proteins, pathways shared with other HDACi.
Most HDACs are enzymes involved in the epigenetic regulation of gene expression at least in part by modulating the acetylation state of core histones and belong to four classes. 1, 5, 38 ITF2357 inhibits class I and class II HDAC.
1,3,4
We could show here that ITF2357 induces hyperacetylation of histones H3 and H4 with an IC 50 similar to that required for its cytotoxic effect. Hyperacetylation was sustained, being already observed at 4 h (data not shown) and further increased at 24 h. Histone hyperacetylation may be at least in part responsible for the modulation of gene expression such as p21 or bcl2 after ITF2357 treatment. 5 Interestingly, ITF2357 also induced hyperacetylation of a-tubulin and this could be observed early (1 h). The tubulin deacetylase, but not HDAC, active site of the HDAC6 enzyme is responsible for tubulin acetylation and is a site targeted by several hydroxamate HDACi, but not by all HDACi. 34, 39 Tubulin hyperacetylation leads to stabilization of microtubules, potentially deregulating their function during cell cycle, aggresome formation in response to the accumulation of unfolded, or misfolded ubiquinated proteins 10, 34, 40 or exocytosis. 24 Indeed HDAC6 inhibition has been proposed as the molecular basis for synergism of HDACi with other anti-cancer agents that act through disruption of microtubule dynamics, 41 or through proteasome/aggresome deregulation. 10, 34, 40 Thus the capacity of ITF2357 to modify tubulin structure in leukemic cells is likely to contribute to its anti-leukemic activity.
An important aspect to consider in the context of antileukemic drugs is the role of the bone marrow microenvironment. We show here that bone marrow-derived human MSCs support the growth of the IL-6-dependent MM line CMA-03 and provide positive signals for freshly isolated AML cells. 17, 18 These leukemic cells displayed a marked increase in survival in the coculture system for at least 2-3 weeks. Most importantly, MM and AML cells cultured on MSCs still responded efficiently to Anti-leukemic activity of the new HDAC inhibitor ITF2357 J Golay et al ITF2357, which was cytotoxic with an IC 50 of 0.3-0.4 mM, which is only marginally higher than that observed when cells were maintained in culture medium alone. This suggests that stimulation by MSCs does not confer significant resistance to ITF2357. [42] [43] [44] Cytotoxicity in co-cultured leukemic cells was not due to apoptosis of the MSC feeder layer since ITF2357 showed Anti-leukemic activity of the new HDAC inhibitor ITF2357 J Golay et al little cytotoxicity for MSCs up to 10 mM. This observation demonstrates the specificity of the pro-apoptotic effect of the drug on leukemic cells and is in agreement with the finding that ITF2357 does not cause apoptosis of normal hepatocytes, 21 and is also less cytotoxic for normal peripheral blood mononuclear cells in vitro.
20
Most strikingly, the drug strongly inhibited the production of several growth and angiogenic factors produced by MSCs. Cultured MSCs secreted IL-6, VEGF, IL-8 as well as IFN-g, in accordance with previous reports. 19, 45, 46 ITF2357 inhibited production of IL-6, VEGF and IFN-g, but not IL-8, with an IC 50 similar to that required for apoptosis induction of leukemic cells (0.25-0.5 mM). These data are in agreement with the ability of the drug to specifically inhibit LPS-induced TNF-a, IL-1a and IL-6 but not IL-8 production by peripheral blood mononuclear cells. 20 Other HDACi have been reported previously to inhibit IL-6 and VEGF production by MM or endothelial cells. 3, 32 To our knowledge this is the first description of the effect of HDACi bone marrow stromal cells. Inhibition of both IL-6 and VEGF is of prime interest since IL-6 is a well-known growth factor for MM cells in a paracrine and autocrine fashion and mediates MM cell growth, migration within the bone marrow as well as drug resistance (reviewed in Sirohi and Powles 15 and Yasui et al. 47 ). It has been recognized as an important target for the control of different types of tumors (reviewed in Podar and Anderson 16 ). VEGF is an important angiogenic factor and a major target for anti-cancer drugs. ITF2357 would therefore have a favorable activity by inducing directly apoptosis of leukemic cells and simultaneously inhibiting growth and angiogenic factors in the bone marrow.
ITF2357 was demonstrated here to have therapeutic activity in a mouse model of AML in SCID mice, using AML-PS, a cell line established by in vivo passage. 28 These cells home in bone marrow, spleen and liver after i.v. inoculation and have maintained the cell surface phenotype of the primary acute leukemia from which they are derived. ITF2357 significantly improved survival in this model, without significant toxicity. AML-PS therefore represents a useful new animal model in which to test the activity of HDACi in AML. In vivo activity of SAHA has been recently published in a similar model of pre-B-ALL in non-obese, diabetic-SCID mice. 48 To conclude, the HDAC inhibitor ITF2357 has been shown here to have a very promising activity profile in MM and AML in vitro and in vivo. In particular, the ability of ITF2357 to induce apoptosis of tumor cells and to inhibit IL-6 and VEGF production by bone marrow multipotent MSCs makes this drug of high interest in terms of biological activity. A phase II study in Crohn's disease has been completed with oral ITF2357, where the compound was well tolerated (Italfarmaco; unpublished data; trial no. EudraCT 2004-004854-19) . Pharmacokinetic and toxicity studies have shown that levels of drug active in vitro against leukemic cells can be reached in vivo. These studies have contributed to the design of two phase I trials of ITF2357 in MM and AML which are presently ongoing. Anti-leukemic activity of the new HDAC inhibitor ITF2357 J Golay et al
